- CordenPharma has committed a multi-year €80 million ($93.1 million) investment to expand sterile injectable manufacturing at its Caponago site in Milan, Italy.
- The expansion is projected to increase total production capacity to up to 500 million injectable units per year, with new aseptic fill-finish lines targeted for completion in 2027 and 2028.
CordenPharma has committed a multi-year €80 million ($93.1 million) investment to expand sterile injectable manufacturing at its FDA- and EMA-approved Caponago site in Milan, Italy. As part of the investment, the company completed a €13 million ($15.1 million) acquisition of an 11,000-square-meter commercial building and 26,000 square meters of land adjacent to its existing late-stage aseptic fill-finish manufacturing area. The acquisition was finalized on July 28, 2026, increasing the site footprint by more than 50%.
The new facility will provide space for a minimum of four aseptic fill-finish lines, four visual inspection lines and four additional packaging lines. It can also accommodate customer-owned lines, large-scale lyophilization and auto-injector assembly. The facility will support injectable therapeutics based on peptides, LNPs, small molecules, biologics and oligonucleotides across formats including pre-filled syringes, liquid or lyophilized vials, cartridges and auto-injectors.
CordenPharma is also expanding an existing operational area at the Caponago site with two new aseptic fill-finish isolator lines. These include a clinical and small-scale commercial line for pre-filled syringes, vials and cartridges, and a high-speed pre-filled syringe and cartridge line capable of producing more than 500,000 units per day. The company is also expanding automatic secondary packaging for pre-filled syringes, vials and ampoules and doubling analytical capacity. Completion of the two new isolator lines is targeted for mid-2027 and 2028, respectively.
The combined expansion is projected to increase total capacity to up to 500 million injectable units per year. CordenPharma said the additional capacity will address demand for sterile injectable outsourcing across oncology, obesity, diabetes and inflammatory diseases, as well as complex modalities including peptide-based GLP-1 therapeutics, oligonucleotides, LNPs, biosimilars and other biologics. The company will also offer integrated drug substance-to-drug product capabilities through its global network.
“The support of our shareholders, Astorg, underscores our commitment to advancing sterile injectable manufacturing at CordenPharma Caponago. The investment will strengthen the company’s capabilities in manufacturing drug products using complex modalities and support rising demand for injectable outsourcing.”
Dr. Michael Quirmbach, president and CEO of CordenPharma Group
